GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
GW Pharma’s cannabis-derived medicine for epilepsy has won European endorsement, more than a year after the British drugmaker secured its landmark US approval.
The medicine, christened Epidyolex in the EU, is a plant-derived formulation of cannabidiol (CBD). It was approved in June by the US authorities and launched in the region in November. The London-based company generated nearly $102 million selling the drug in the first half of this year — and has treated over 12,000 patients in the United States.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.